Table 3 P Values for Association of TILs and TcellinfGEP with Clinical Outcomes Using a Multivariate Model

From: Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

Biomarker

Chemotherapy

Pembrolizumab

N

BORa

PFSb

OSb

N

BORa

PFSb

OSb

TcellinfGEP

146

0.788

0.384

0.760

165

0.006+

3.83e-05+

3.38e-04+

TILsc

146

0.182

0.710

0.938

165

0.461

0.297

0.198

  1. BOR best overall response, OS overall survival, PFS progression-free survival, TcellinfGEP T-cell‒inflamed gene expression profile, TIL tumor-infiltrating lymphocyte.
  2. aBOR: Logistic regression model.
  3. bPFS and OS: Cox model. All models include the baseline ECOG performance status as a covariate.
  4. cTILs are square-root transformed.
  5. +: indicates the observed association is positive.
Back to article page